Loading...
Market
How many countries will be conducting clinical trials for MED6-189 by December 31, 2024?
2
Resolution / Starting Odds
1-2 countries • 25%
3-4 countries • 25%
5-6 countries • 25%
7 or more countries • 25%
ClinicalTrials.gov and global health news reports
Story
Kalihinol Analog MED6-189 Shows Promise Against Drug-Resistant Malaria Parasite
Sep 27, 2024, 07:28 AM
A synthetic compound, MED6-189, a kalihinol analog, has shown promise against both drug-sensitive and drug-resistant strains of the malaria parasite Plasmodium falciparum. The compound disrupts apicoplast function and vesicular trafficking in the parasite, effectively killing it. This discovery, highlighted in a study published in Science, demonstrated efficacy in a humanized mouse model of malaria. Research by @UCRiverside and @ScienceMagazine indicates that MED6-189 could be a significant advancement in the fight against malaria.
View original story
Similar markets
1-2 countries • 33%
3-4 countries • 33%
5 or more countries • 33%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
0-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
31 or more countries • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
0 • 25%
1 - 2 • 25%
3 - 4 • 25%
5 or more • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Less than 5 • 25%
5 to 10 • 25%
11 to 20 • 25%
More than 20 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%